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 1872 words 
 
We appreciate the efforts of the editors of the Journal of Clinical Epidemiology to provide a fo-
rum for discussion of pragmatismi in randomized trials (RCTs), with many items in recent years, 
including three in this issue by Dekkers et al ii, Zuidegeest et al. iii and Riddle iv. We are encour-
aged that these three authors agree on the importance of pragmatism and the relevance of 
PRECIS-2 to RCT designv, our tool to promote better matching of the choices made during de-
sign with the intended use of that trial’s results. We thank them for their insightful comments re-
lating to the varied meanings of generalizability, and the relationship between pragmatic and 
explanatory characteristics and internal validity and applicability (which we use as a synonym 
for generalizability) of trial results, to which we respond below. 
 
Dekkers et al conclude their commentary as follows:  “Unfortunately, the PRECIS authors sup-
pose that a pragmatic trial is widely generalizable, to different contexts and settings…”. We do 
not suppose this. In fact Dekkers et al correctly describe our approach in an earlier sentence in 
their paper in which they refer to PRECIS-2 as having the ‘objective to match the trial design ‘‘to 
how the trial results are intended to be used’’. Our conception of PRECIS-2 is that it is to be 
used by trialists to design a trial whose results are applicable to a context in which they, the trial-
ists, are intending the results to be used. At the design stage, trialists carefully consider the 
population and health care delivery context required for their intervention to be successful, use 
this to formulate a realistic view of the applicability of their trial results, and then match the trial 
design to that context. The full quote from the PRECIS-2 paper is as follows: “The PRECIS-2 
tool focuses on trial design choices which determine the applicability of a trial. Applicability (the 
ability for a trial result to be applied or used in a particular situation) is the outcome of these 
choices, which affect the ease with which the trial results can be applied to and by the usual 
community of users of the intervention in the settings in which the trial designers envisioned it 
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being used”.  This misunderstanding by Dekkers et al and others is a clear signal that we need 
to be more explicit about the process by which designers formulate their intentions for applica-
bility in our next update of PRECIS. 
 
Dekkers et al end their paper by stating that “one may question whether ……. trialists are in a 
position to judge such a broad applicability of their own trial”. We do believe that a pragmatic 
trial, designed to be applicable to a particular population and health system context, and using 
recruitment, follow up, analysis and other design choices that most closely mimic care delivery 
in that context, may well be applicable to other similar contexts that lie well outside of the trial 
designers’ experiences or intentions.  But this judgement of similarity, and thus of applicability is 
really a decision about local implementation, and is not the responsibility of the trial design 
team, but of the reader who may be a decision maker and potential user of the evidence provid-
ed in the published RCT.  We long ago designed a different tool intended to ease the task of 
such readers in making decisions using RCT publications. The CONSORT extension for Prag-
matic Trialsvi is intended for use when the results of a trial are being written up for publication. It 
provides guidance to the writers of that publication, presumably part of the trial design team, so 
that they include in their trial publication all the information on the context of their trial needed by 
future readers of that paper to judge applicability of the results to their own context, where they 
may be considering implementing the intervention tested in that randomized trial.   
 
In summary, the issue of applicability is dealt with in two stages, by different actors. In the first 
stage, trial designers use the PRECIS-2 tool to match their trial design to a context in which 
they, the trial team, deem the intervention would be usable and the RCT results applicable. At 
the second stage, health system decision makers use the information in the published RCT to 
contribute to the decision on implementation of the tested intervention in their own context. This 
also answers the questions raised by Dekkers et al. as to whether a trial can be equally applica-
ble in Finland and China, in primary care and in intensive care: the trial designers are unlikely to 
be able to judge applicability between two such different countries, but we would speculate that 
intensive care units may be more similar to each other across countries than are their primary 
care systems. Mainly, we suggest that these are second stage judgements, to be made by local 
decision makers in any setting considering implementation of the tested intervention.  In other 
words, separately by Finnish and Chinese decision makers as they consider implementing the 
same intervention in their own contexts. Most often this requires that the decision makers return 
to the published RCT of that intervention, as well as having a nuanced understanding of any 
existing systematic reviews of RCTs of that intervention, which might be aggregating outcomes 
across very different contexts.  
 
We agree with Zuidgeest et al that designing a pragmatic trial would be difficult if every imagi-
nable characteristic of the context to which the trial is generalized had to be explicitly matched, 
and that it is acceptable to ignore matching on characteristics that are known not to affect out-
come. Unfortunately, we seldom know the full pathway of action for drugs, much less that for 
complex interventions operating through multiple pathways, and so it is very hard to know which 
potential matching characteristics can be ignored. For this reason we implicitly prioritized a 
number of features in PRECIS-2 and focussed on matching aspects typically under the control 
of the designers of the trial themselves to the context in which they deem the trial applicable: 
these nine characteristics form the domains of PRECIS-2: eligibility criteria, recruitment pro-
cesses and intensity of follow up of participants, the rigidity with which delivery and participant 
adherence are enforced, the approach to primary outcome and analysis, and two, setting and 
organization, intended to capture the local peculiarities of the health systems and contexts in 
which the designers consider that trial results will be applicable. We do not prescribe detailed 
criteria for these last two domains because at this stage we do not know how specific attributes 
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influence generalizability. We look forward to the Get Real Consortium work, by Zuidegeest et 
al, on the effects on trial conduct, ethics and feasibility of different design choices, as it may 
provide empirically tested and robust guidance to trial designers on different options for balanc-
ing practical and pragmatic aspects of their proposed trial. But PRECIS-2 users, such as trial 
designers, funders and readers of randomized trials should keep in mind that the act of general-
ization is likely to remain an act of subjective judgement, not statistical extrapolation. 
 
Zuidgeest et al correctly point out that the PRECIS-2 paper says little about the comparator arm, 
and excludes it from the PRECIS wheel even though choice of comparator may dramatically 
influence the estimate of effect size. We agree that the choice of comparator is difficult and criti-
cal and yet we say only: “In pragmatic trials the comparator is usual care. In explanatory trials it 
may not be. In PRECIS-2 the domains are based on the assumption that the trial is two armed, 
one of which is usual care with no changes. If usual care is not the comparator, or there are 
multiple intervention arms that are very different from each other, then the arms will need to be 
scored separately”. We suggest that the definition of usual care (or the chosen comparator) is 
the responsibility of the trial design team, as is the design of intervention arm(s), and we don't 
presume to direct the trial design team on what they should select as a comparator. We find it 
difficult to suggest more than this without narrowing the value of PRECIS-2 by recommending 
one or other “standard” for usual care which may even slant guidance towards particular set-
tings. Detailed description of the comparator arm is crucial to the second stage judgement of 
applicability mentioned above and for this reason our CONSORT extension for pragmatic trials 
specifies that the comparator arm(s) should be described in as much detail as the intervention 
arm(s).  
 
Riddle points out that there are times when biological mechanisms, rather than “real world” im-
pact of interventions must be studied, and that explanatory approaches to trial design are then 
completely appropriate. We agree.  We also agree with Riddle that trial designers need to keep 
a careful eye on trial quality, in relation to internal validity.  These issues lie outside the scope of 
PRECIS-2 but we concur that a pragmatic trial conducted poorly, in ways that undermine inter-
nal validity, is of little use for decision support. However, we do not agree with Riddle that trial 
design choices such as definition of usual care, and treatment standardization have any impact 
on internal validity; indeed, we would argue that these particular items impact only on external 
validity/applicability/generalizability. Trialists need a nuanced understanding of which issues in 
design are linked to internal validity (bias), and which to external validity (generalizability, ap-
plicability), in order to design their trials appropriately. 
 
Zuidgeest et al correctly point out that PRECIS-2 aims to help all trial designers match their de-
sign to the intended purpose of their trial, but its’ descriptions of the attributes that promote an 
explanatory approach are less detailed than those which promote a pragmatic approach. They 
suggest that this is not helpful since the characteristics that promote clear testing of an hypothe-
sis about mechanism are unlikely to be the simple inverse of those which promote applicability. 
This is a valid criticism, and at our next update of PRECIS we will consider how best to support 
trialists whose intentions are mechanism-oriented and explanatory. We will also consider this 
issue as we update the CONSORT statement on pragmatic trials, where we encourage trialists 
to match the type of conclusions they draw to the capacities of their trial design to support those 
conclusions. 
 
It is, however, worth mentioning that we see many RCTs published with explanatory designs, 
and yet they conclude with a treatment recommendation, which suggests that hypothesis testing 
or mechanism exploration may not have been their main goal. Rather, the presence of a treat-
ment recommendation suggests a pragmatic (decision support) purpose for the trial and that the 
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choice of explanatory design elements represents a mismatch between the trialists’ applicability 
intentions and their design choices. PRECIS-2 is intended to help all trialists match their design 
choices to their intentions, but the most valuable contribution of PRECIS-2 to health systems 
would be to prevent this longstanding problem: trials whose intent is pragmatic but whose de-
sign choices are skewed towards the explanatory end of the spectrum. We quote Schwartz and 
Lellouch: “Most trials done hitherto have adopted the explanatory approach without question; 
the pragmatic approach would often have been more justifiable“.  
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Highlights 
 
RCTs have been the mainstay of evaluation of health and medical interventions for over half a 
century,  but doubts on their applicability to real world contexts has been an increasing topic of 
discussion in recent years. We comment here on the understandings of  PRECIS-2 described in 
three papers in this issue (Zuidegeest, Dekkers, and Riddle) focussing on the issue of who 
judges applicability and when. We point out the focus of PRECIS-2 on designing trials to match 
the intentions of the designers, which might be either applicability to a specific context that the 
designers have in mind, or testing a hypothesis related to a mechanism of action. PRECIS-2 is 
suitable for this purpose, but a different tool, the CONSORT statement extension for pragmatic 
trials is suitable to support the proper description of intervention and context by the authors of 
the trial so that the information in it is of maximum usefulness to potential users or implementers 
of the tested intervention in settings beyond those imagined by the trials designers.  
